92 results about "Bone remodeling" patented technology

The present invention concerns an orthodontic appliance for accelerating the tooth aligning effect and shortening the treatment period, and has an object to provide an appliance which can bring about higher aligning effect than usual ways by giving vibration to tooth to be aligned to activate bone remodeling of the targeted tooth and the alveolar bone and enhance the shift of the tooth. This appliance includes a vibrating element and a dental mouthpiece having the vibrating element built therein. The provision of the vibrating element in the dental mouthpiece facilitates the application of vibration and handling, and continues the treatment safely even at home. The inner shape of the dental mouthpiece serves aligning treatment as well as acceleration of the effect.

A method for treating a patient to promote bone growth, comprising: administering to the patient a therapeutic amount of a bone remodeling agent effective to stimulate bone growth, and a dietary supplement comprising calcium and phosphorus, in a therapeutic amount effective to prevent a deficiency in the amount of calcium or phosphorus available for bone growth.

The invention provides polynucleotides and polypeptides that are co-expressed with genes known to be involved in bone remodeling and osteoporosis. The invention also provides expression vectors, host cells, and methods for making a polypeptide, for screening or purifying ligands, and for diagnosing disorders associated with bone remodeling or osteoporosis.

Methods are provided for regulating bone remodeling or tooth movement, comprising allowing a functional appliance to exert a force on oral or maxillofacial bone, muscle, or soft tissue, or one or more teeth of a patient in need thereof; and administering an effective amount of light to the oral or maxillofacial bone, muscle, or soft tissue, or one or more teeth, wherein the light is administered before, during, or after the force is exerted. Methods are also provided for regulating bone remodeling, comprising administering an effective amount of vitamin D to an oral or maxillofacial bone, muscle, or soft tissue, or to one or more teeth of a patient in need thereof; and administering an effective amount of light to the oral or maxillofacial bone, muscle, or soft tissue, or to the one or more teeth. Apparatuses useful for providing light therapy and/or vitamin D is also provided.

This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.

The invention discloses a metal artificial bone trabecula for medical purposes. The structural design of the metal artificial bone trabecula is completed by a computer, and then inputted in an electron beam fusion former; the high temperature generated by electron beams is used to carry out the stratified scanning and high-temperature fusion to titanium alloy powder in the former so as to obtain the metal artificial bone trabecula with bio-cancellous bone morphology, strength and elasticity modulus and a rough and loose outer surface formed by a porous structure. The obtained artificial bone trabecula has mechanical and biological characteristics similar to a human bone, high surface friction coefficient, stable structure and wide range of application, and is applicable to various bone defects, bone filling, bone supporting, bone remodeling and bone repair in a human skeletal system as well as bone restoration of bone remodeling and substitute bone of different bone joints of a human body.

This invention relates to a process to facilitate osteochondral bone remodeling in a subject by inducing regeneration of this bone to a healthy, vascularized state capable of supporting the underlying hyaline cartilage of articular joints and spinal discs, both biomechanically and metabolically and to deliver a bioactive agent. This process involves the steps of: administering an effective amount of an injectable in situ curing biomaterial composite to a site. The biomaterial composite product is prepared by a process involving the steps: admixing an alginate solution with a nonporous aggregate of β-tricalcium phosphate, in a sufficient amount to initiate polymerization of the alginate solution, to form a hydrogel having from between 10 to 20 percent by volume of β-tricalcium phosphate.

The present invention relates to a pharmaceutical composition for the treatment of metabolic bone disease and the method of preparation thereof, and more particularly, to an improved pharmaceutical composition for the therapeutic treatment of metabolic disease and the method of preparation thereof, wherein said composition is prepared as a composite pharmaceutical agent which comprises calcitriol; which reduces the rate of spine fractures and increases bone density; alendronate, a bone resorption inhibitor, as two main active ingredients in an optimal mixing ratio to exert the greatest synergistic therapeutic effect; and adequate amount of other additives such as a resorption fortifier of alendronate. Thereof, the pharmaceutical composition according to the present invention can inhibit hypercalcemia caused when administered by calcitriol alone, compensate the inhibitory activity of bone remodeling caused by alendronate due to the presence of calcitriol, and improve drug compliance associated with the usual difficulty in administration as well as a side effect in esophagus, thus effectively preventing the occurence of osteoporosis.

A vestibular electronic orthodontic appliance expediter constituted of a lingual sub-member and a buccal sub-member, the lingual sub-member arranged to fit a lingual contour of a gum of a patient, the buccal sub-member arranged to fit a buccal contour of a gum of the patient; a control circuitry; a power supply; a plurality of lingual electrodes, each associated with a particular tooth socket; and a plurality of buccal electrodes, each associated with a particular tooth socket. Either a first or a second type current is generated between lingual and buccal electrodes responsive to the control circuitry. Biochemical molecules involved in bone remodeling, augmented by the electric currents, may be applied to the expediter as a layer of gel containing those molecules on the expediter surface facing the gum tissue. Temperature control enhances the gel effects. pH measurement, as indicators of the cellular response to the combined treatment is further provided.

The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLT1, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDR1 and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.

A method and apparatus to improve and accelerate orthodontic tooth movement and alveolar bone apposition and resorption, constituted of a device providing biocompatible contact anode in contact with gingival epithelia at the area of osteoclastic activity, and biocompatible contact cathode in contact with gingival epithelia at the area of osteoblastic activity, arranged to apply electric current across the anode and the cathode to stimulate alveolar bone remodeling. The method and apparatus provide for an electronic circuit that is pre-programmed via wireless communication to adjust the electric current magnitude and time duration so as to enhance tooth movement, oseteogenesis, and osteoclasia.

A device for treating a bone includes a first clamp member sized and shaped to be mounted over a bone laterally across a fixation plate positioned along a length of the bone. In addition, the device includes a second clamp member coupleable to the first clamp member so that, when the first and second clamp members are coupled together in an operative position, the first and second clamp members extend about at least a portion of a periphery of the bone. The second clamp member includes a spring feature biased toward an initial configuration and deflectable toward a second configuration away from the bone.

The object of the present invention is to provide a calcium phosphate-collagen fiber composite which has an excellent mechanical property, can induce bone replacement by rapid bone remodeling, and can be used in a high-load region. The object can be solved by a porous composite comprising a calcium phosphate crystal and a collagen fiber at a weight ratio of 80:20 to 20:80, wherein (1) a bioabsorbability of the porous composite is graded, and (2) the density of the porous composite determined by gravimetric method is 300 to 1500 mg/cm³.

The invention belongs to the technical field of cell in-vitro culture, and relates to mesenchymal stem cells/osteoclast precursor cells/follicular cells co-culture model which is used for rapidly screening antiosteoporosis drugs. A co-culture system is characterized in that the mesenchymal stem cells and the osteoclast precursor cells are directly cultured in a contacting manner in a lower layer culture chamber in an upper and a lower layers of culture systems, the follicular cells are cultured on a semipermeable membrane of the upper layer culture chamber in an adherence manner: the culture system is used for simulating the bone remodeling process of bone tissues under an in-vitro condition; the cell co-culture model is used for rapidly screening the antiosteoporosis drugs according to the influence of the drugs on the release of alkaline phosphatase, tartrate-resistant acid phosphatase and estrogen.

A medical or dental implant which contains a metal material selected from the group consisting of titanium or an alloy thereof, wherein at least part of the surface of the metal material is coated with a layer of a polyunsaturated fatty acids (PUFA). In a preferred embodiment, the implant has been exposed to UV radiation for at least 30 seconds before, simultaneously with and/or after the coating with PUFA. Depending on the concentration of polyunsaturated fatty acids on the surface, at least parts of the implant exhibits improved effect on adhesion of mineralized and/or hard tissue, such as on bone remodeling and/or improved biocompatibility, or alternatively inhibits adhesion of mineralized and/or hard tissue to the implant. The metal material is preferably titanium, the polyunsaturated fatty acid is preferably EPA.

The invention relates to a medicine for curing osteonecrosis, belonging to the field of regenerative medicine engineering. Human amniotic mesenchymal cells (hAMCs) are used as cell source for cellular transplantation and tissue organization so as to cure the osteonecrosis and to provide a new way for repairing a damaged osseous tissue and reorganizing tissues. Based on the multi-lineage differentiation potential of the hAMCs, osteocytes, osseous tissues and vascular endotheliums can be differentiated in the human body, thereby completing the processes of osteanagenesis, bone remodeling and vascularization and forming a new osseous tissue integrated with the tissues of the patient.

The invention discloses drug loading biological activity glass complex calcium phosphate bone cement and application thereof. According to the invention, drug loading biological activity glass microspheres are added into the calcium phosphate bone cement, the in vivo degradation rate of the biological activity glass microspheres is relatively high, a porous structure inside the calcium phosphate bone cement can be adjusted, a bone-like apatite layer can be formed on the surface of each biological activity glass microsphere, and the drug loading biological activity glass complex calcium phosphate bone cement has good biological activity; and simultaneously, loaded drugs are released while the biological activity glass microspheres are degraded, so that the bone cement has the effects of bone remodeling and drug therapy; and the cell proliferation is promoted by using strontium-doped octacalcium phosphate modified alpha-TCP bone cement. The calcium phosphate bone cement has moderate timeof coagulation, is good in syringeability, mechanical strength and biocompatibility, and meets clinic requirements of bone repair.